Archives
-
Sulfo-Cy5 NHS Ester in Immune Imaging
2026-10-06
Sulfo-Cy5 NHS ester offers a far-red, aqueous-phase approach to biomolecule visualization. This article examines how its labeling chemistry can support mechanistic interpretation of immune-cell and tumor-microenvironment studies without confusing fluorescence localization with biological causality.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-10-05
The reference study identifies CD44-mediated metabolic rewiring as a functional dependency of IDH-mutant leukemia, connecting pentose phosphate pathway activity and NADPH production with sustained R-2HG synthesis. Its isogenic genetic models and combination analyses provide a mechanistic rationale for studying CD44 alongside mutant-IDH inhibition, while remaining preclinical and requiring validation in clinically diverse disease settings.
-
MEK/ERK, c-Myc, and TERT Polycomb Repression
2026-10-05
A 2024 preprint identifies MEK1/2–ERK signaling and c-Myc:MAX as cooperating regulators that protect TERT from PRC2-associated repression in human embryonic stem cells. The findings connect kinase signaling, transcription-factor occupancy, and opposing H3K27 methylation and acetylation states, while also defining important limits for interpretation beyond the studied stem-cell model.
-
mRNA–LNP Research: What the 2025 Protocol Adds
2026-10-04
The 2025 Nature Protocols paper presents an end-to-end, small-scale framework for designing, producing, assessing, and formulating research-grade mRNA. Its main contribution is integration: sequence design, DNA template preparation, in vitro transcription, quality control, lipid nanoparticle formulation, and cell-based evaluation are treated as one evidence-linked workflow rather than isolated tasks.
-
Verbascoside in PKC/NF-κB Research: Evidence
2026-10-03
A source-grounded overview of Verbascoside as a proposed PKC/NF-κB inhibitor, its relevance to osteoclastogenesis and inflammatory signaling, and the limits of connecting catalog claims with published neuroinflammation findings.
-
APEX2-Dependent TERT Expression in Human Stem Cells
2026-10-02
This preprint identifies APEX2, but not its paralog APEX1, as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells. RNA-seq and chromatin immunoprecipitation link this function to repetitive DNA, especially MIR sequences within TERT intron 2, suggesting that repair of damage-prone chromatin may influence telomerase regulation.
-
Hexa-Acylated LPS Boosts Cancer Immunotherapy
2026-10-01
The reference study shows that the molecular structure of gut microbiota-derived lipopolysaccharide, rather than the presence of LPS-producing bacteria alone, can influence anti-PD-1 treatment response. Functional metagenomics and mouse experiments identify hexa-acylated LPS as a TLR4-dependent enhancer of antitumour immunity and a potential biomarker of immunotherapy responsiveness.
-
Streptavidin-Cy3 Workflows for Biohybrid Microrobots
2026-10-01
Streptavidin-Cy3 adds a modular fluorescence readout to biohybrid microrobot studies, helping researchers map localization, barrier penetration, and biomolecular encounters without mistaking signal for therapeutic proof. This guide connects biotin-based labeling with practical IHC, IF, ISH, and flow cytometry workflows, including starting parameters and troubleshooting strategies.
-
AG-221 (Enasidenib) in IDH2-Mutant AML Research
2026-09-30
Build more informative IDH2-mutant AML assays with AG-221 (Enasidenib), combining oncometabolite measurement, differentiation readouts, and metabolic profiling. This workflow distinguishes direct 2-hydroxyglutarate reduction from broader cytotoxicity and helps test CD44-linked resistance mechanisms.
-
4-MUG for Lysosomal Enzyme Activity Assays
2026-09-30
4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) converts β-glucosidase and β-glucocerebrosidase activity into a sensitive fluorescent signal. This article focuses on assay interpretability, pH-aware measurement, and how 4-MUG can evaluate functional outcomes in emerging GBA1-mRNA research.
-
CLK2 Inhibition and Platinum Resistance in Ovarian Cancer
2026-09-29
The reference study identifies Cdc2-like kinase 2 (CLK2) as a functional driver of platinum resistance in ovarian cancer, rather than merely a correlational biomarker. Its central mechanism links CLK2 to BRCA1 Ser1423 phosphorylation and enhanced DNA damage repair, suggesting a rationale for testing CLK2-directed strategies alongside platinum treatment.
-
Streptavidin-Cy3 for NPC Metastasis Assays
2026-09-29
Use Streptavidin-Cy3 to convert biotinylated antibodies, probes, and molecular targets into bright, spatially resolved signals across NPC metastasis workflows. This guide connects super-enhancer RNA biology with practical IHC, ISH, immunofluorescence, and flow cytometry optimization.
-
GSK343 Workflows for EZH2 Epigenetic Studies
2026-09-28
GSK343 is a cell-permeable EZH2 inhibitor for connecting PRC2 activity, H3K27me3 loss, and cancer-cell phenotypes in controlled in vitro experiments. Its strongest value is as a mechanistic tool: researchers can pair target engagement with proliferation, apoptosis, autophagy, or TERT-focused assays while avoiding unsupported assumptions about in vivo efficacy.
-
Puromycin Aminonucleoside for Podocyte Injury Models
2026-09-28
Use Puromycin aminonucleoside to connect podocyte structural damage with proteinuria and glomerular pathology in carefully controlled renal studies. This guide lays out a practical in vitro-to-in vivo workflow, dose-finding safeguards, and a clearly bounded way to borrow assay-design ideas from an unrelated epigenetics study.
-
AngII Drives M1 Polarization via Cx43/NF-κB
2026-09-27
The study links angiotensin II–induced inflammatory polarization of RAW264.7 macrophages to increased Cx43 and NF-κB p65 signaling. Inhibiting either pathway reduced M1-associated markers, supporting a role for the Cx43/NF-κB axis while leaving questions about channel specificity, pathway order, and relevance beyond this cell model open.